Global Leading Market Research Publisher QYResearch announces the release of its latest report “Steroid Induced Glaucoma - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. This comprehensive study delivers an authoritative analysis of the global steroid induced glaucoma market, integrating historical impact data (2021-2025) with forward-looking forecast calculations (2026-2032). Covering critical dimensions such as market size, market share, demand trajectories, industry development status, and long-term growth projections, this report serves as an essential strategic resource for stakeholders across ophthalmology, glaucoma therapeutics, pharmaceutical manufacturers, and vision care sectors. For ophthalmologists, glaucoma specialists, and healthcare systems managing the growing burden of ocular hypertension and optic nerve damage—steroid induced glaucoma represents a significant iatrogenic condition that arises from the widespread use of corticosteroids across multiple medical specialties. Corticosteroids are among the most prescribed medications globally, used for their potent anti-inflammatory and immunosuppressive effects across dermatology, pulmonology, rheumatology, and ophthalmology. However, prolonged or excessive use—whether administered topically (eye drops), systemically (oral or injectable), inhaled, or periocularly—can lead to increased resistance to aqueous humor outflow through the trabecular meshwork, resulting in elevated intraocular pressure (IOP) that, if undetected or untreated, can progress to permanent optic nerve damage and vision loss. This condition affects patients with personal or family history of glaucoma, children, and those on long-term steroid therapy at highest risk, creating a substantial market for monitoring, prevention, and treatment interventions across ophthalmology. Market Growth Outlook: A US$1.82 Billion Opportunity at 6.1% CAGR The global steroid induced glaucoma market demonstrated robust growth fundamentals in 2025, with total market value estimated at US$ 1,207 million. According to QYResearch's latest industry analysis, this figure is projected to expand to US$ 1,816 million by 2032, representing a steady compound annual growth rate (CAGR) of 6.1% over the forecast period. This sustained growth trajectory reflects the increasing prevalence of chronic diseases requiring long-term steroid therapy, growing awareness of steroid-induced ocular complications, and expanding treatment options for managing steroid-induced ocular hypertension. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】 https://www.qyresearch.com/reports/6090703/steroid-induced-glaucoma Product Definition: Secondary Glaucoma from Corticosteroid Exposure Steroid-induced glaucoma is a form of secondary open-angle glaucoma that occurs due to prolonged or excessive use of corticosteroids across any route of administration. The underlying pathophysiology involves corticosteroid-induced changes in the trabecular meshwork, increasing resistance to aqueous humor outflow and resulting in elevated intraocular pressure (IOP). This sustained IOP elevation, if left untreated, can damage the optic nerve and lead to irreversible vision loss. Pathophysiology: Trabecular meshwork: Primary site of steroid-induced damage Outflow resistance: Increased resistance to aqueous humor drainage IOP elevation: Secondary ocular hypertension Optic nerve damage: Pressure-induced axonal injury Visual field loss: Progressive vision deterioration Risk Factors: Steroid administration route: Topical (highest risk), periocular, systemic Duration: Prolonged or chronic steroid use Dosage: Higher cumulative steroid exposure Personal history: Pre-existing glaucoma or ocular hypertension Family history: Genetic predisposition to steroid responsiveness Age: Children at elevated risk Underlying conditions: Diabetes; high myopia; connective tissue disorders Corticosteroid Types Associated with Glaucoma: Prednisolone: Commonly used: Ophthalmic preparations; systemic therapy Potency: Moderate to high glucocorticoid activity Risk profile: Well-documented association with IOP elevation Applications: Allergic conjunctivitis; uveitis; postoperative inflammation Dexamethasone: Commonly used: Ophthalmic drops; intravitreal implants; systemic therapy Potency: High glucocorticoid activity Risk profile: Significant IOP elevation risk; dose-dependent Applications: Inflammation; macular edema; allergic conditions Other Steroids: Fluorometholone: Lower IOP elevation risk; milder potency Loteprednol: Lower IOP elevation risk; newer formulations Triamcinolone: Intraocular and periocular use; significant IOP risk Systemic steroids: Oral, IV, inhaled; cumulative risk Clinical Presentation: Insidious onset: Gradual IOP elevation without symptoms Bilateral: Often affects both eyes with systemic steroid use Unilateral: May present in one eye with topical or periocular administration Variable severity: IOP elevation ranges from mild to severe Reversible: IOP typically returns to baseline after steroid discontinuation in early stages Market Drivers and Structural Trends Widespread Corticosteroid Use: Corticosteroids are among the most commonly prescribed medications: Ophthalmology: Postoperative inflammation; uveitis; allergic conjunctivitis Dermatology: Eczema; psoriasis; contact dermatitis Pulmonology: Asthma; COPD; interstitial lung disease Rheumatology: Autoimmune conditions; inflammatory arthritis Gastroenterology: Inflammatory bowel disease Chronic Disease Prevalence: Increasing prevalence of chronic conditions drives steroid use: Autoimmune diseases: Growing incidence of inflammatory conditions Respiratory diseases: Asthma and COPD affecting millions Allergic conditions: Atopic dermatitis; allergic rhinitis Ophthalmologic conditions: Uveitis; dry eye; postoperative inflammation Iatrogenic Condition Awareness: Growing awareness of steroid-induced glaucoma drives market growth: Screening protocols: IOP monitoring for high-risk patients Risk stratification: Identification of steroid responders Prevention strategies: Use of lower-risk steroids in susceptible patients Treatment protocols: Management of steroid-induced IOP elevation Treatment Options Expansion: Expanding therapeutic options for glaucoma management: Prostaglandin analogs: First-line IOP-lowering agents Beta-blockers: Established treatment options Carbonic anhydrase inhibitors: Oral and topical formulations Rho kinase inhibitors: Newer mechanism of action Minimally invasive glaucoma surgery (MIGS): Surgical options Segment Analysis and Market Dynamics Segment by Corticosteroid Type: Prednisolone: Largest segment; ophthalmic and systemic use; well-established association Dexamethasone: Significant segment; high potency; intravitreal implants Other: Fluorometholone; loteprednol; triamcinolone; systemic agents Segment by End User: Hospital: Largest segment; ophthalmology departments; surgical centers; inpatient management Retail Pharmacy: Community pharmacies; prescription dispensing Others: Specialty pharmacies; mail-order pharmacies Competitive Landscape: Key Manufacturers The global steroid induced glaucoma market features established pharmaceutical companies with ophthalmology and glaucoma expertise. Key manufacturers profiled in the report include: Novartis AbbVie Bausch & Lomb Pfizer Thea Pharma Sun Pharmaceutical Ocular Therapeutix Glaukos Alcon Santen Pharmaceutical SpyGlass Pharma Strategic Outlook and Exclusive Market Insights The Iatrogenic Condition Paradigm: From an industry analyst's perspective, steroid induced glaucoma represents a significant iatrogenic condition driven by the widespread use of corticosteroids across medicine. The condition's incidence correlates directly with steroid prescribing patterns, creating a predictable market for monitoring, prevention, and treatment. As chronic diseases requiring long-term steroid management increase globally, the addressable population for steroid-induced glaucoma screening and intervention continues to expand. Risk Stratification and Prevention: Risk stratification is central to steroid-induced glaucoma management: High-risk patients: Pre-existing glaucoma; family history; children Moderate risk: Diabetes; high myopia; long-term steroid users Lower risk: Short-term steroid use; no known risk factors Identifying high-risk patients enables targeted IOP monitoring and prophylactic use of lower-risk steroid formulations. Steroid Formulation Evolution: The development of lower-risk steroid formulations represents a significant market trend: Loteprednol etabonate: Lower IOP elevation risk; effective anti-inflammatory Fluorometholone: Milder steroid with lower IOP risk Sustained-release implants: Controlled delivery with monitoring protocols Combination products: Steroid with IOP-lowering agents Geographic Market Dynamics: North America: Largest market; strong ophthalmology infrastructure; chronic disease prevalence Europe: Advanced market; regulatory framework; established glaucoma care Asia-Pacific: Fastest-growing region; increasing steroid use; expanding ophthalmology services; China, Japan as growth markets Emerging Markets: Developing healthcare infrastructure; growing chronic disease burden Future Technology Trajectories: The steroid induced glaucoma market will be shaped by: Risk prediction: Genetic markers for steroid responsiveness Monitoring technology: Home IOP monitoring devices Lower-risk steroids: Novel anti-inflammatory agents without IOP effects Combination therapies: Prophylactic IOP-lowering with steroid therapy Early intervention: Improved detection and treatment algorithms Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp